Junjie Zhao
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Pretreatment intratumoral mature TLSs in non-clear cell renal cell carcinoma are associated with response to immunotherapy rechallenge.
Journal: Journal for immunotherapy of cancer
Published: May 11, 2026
Machine learning derived proliferating T cell-related signature: a novel biomarker for prognosis and treatment efficacy in clear cell renal cell carcinoma.
Journal: International immunopharmacology
Published: December 04, 2025
Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Journal: JAMA oncology
Published: August 14, 2025
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma in Children and Adolescents.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: September 30, 2024
Tertiary lymphoid structures potentially promote immune checkpoint inhibitor response in SMARCB1-deficient medullary renal cell carcinoma.
Journal: NPJ precision oncology
Published: July 11, 2024
Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.
Journal: Molecular cancer
Published: April 21, 2024
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma.
Journal: European journal of medical research
Published: April 20, 2024
Decade-long insights into transperineal prostate biopsy in a West China population: temporal trend, targeted and repeat biopsies, and pathological characterization: a comparative study - retrospective cohort.
Journal: International journal of surgery (London, England)
Published: April 16, 2024
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Journal: Cancer treatment reviews
Published: March 07, 2024
Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets.
Journal: Nature communications
Published: March 06, 2024
Last Updated: 09/26/2026